Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Amylin (AMLN), Eli Lilly (LLY) and Alkermes (ALKS) said a once-weekly injection of exenatide long-acting release
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury